KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation & Amortization (CF) (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Depreciation & Amortization (CF) data on record, last reported at $130000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 11.56% year-over-year to $130000.0; the TTM value through Dec 2025 reached $548000.0, down 23.68%, while the annual FY2025 figure was $548000.0, 23.68% down from the prior year.
  • Depreciation & Amortization (CF) reached $130000.0 in Q4 2025 per AQST's latest filing, down from $139000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $755000.0 in Q1 2021 and bottomed at $130000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $398100.0, with a median of $307000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): rose 17.63% in 2023, then plummeted 68.52% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $731000.0 in 2021, then crashed by 45.69% to $397000.0 in 2022, then grew by 17.63% to $467000.0 in 2023, then tumbled by 68.52% to $147000.0 in 2024, then fell by 11.56% to $130000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $130000.0 in Q4 2025, $139000.0 in Q3 2025, and $140000.0 in Q2 2025.